Online inquiry

IVTScrip™ mRNA-Anti-B7, BMS-188667(Cap 1, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ4370MR)

This product GTTS-WQ4370MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD80&CD86 gene. The antibody can be applied in Rheumatoid arthritis (RA) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_005191.4; NM_001206924.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 941; 942
UniProt ID A0N0P2; P42081
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-B7, BMS-188667(Cap 1, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ4370MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ5436MR IVTScrip™ mRNA-Anti-tcdA, CDA 1(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CDA 1
GTTS-WQ11032MR IVTScrip™ mRNA-Anti-ERBB2&ERBB3, MCLA-128(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MCLA-128
GTTS-WQ12865MR IVTScrip™ mRNA-Anti-TLR2, OPN-305(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA OPN-305
GTTS-WQ5316MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, CD20-TCB (2:1)(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CD20-TCB (2:1)
GTTS-WQ246MR IVTScrip™ mRNA-Anti-B4GALNT1, 14.18 mAb(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA 14.18 mAb
GTTS-WQ7069MR IVTScrip™ mRNA-Anti-FAP, FAP-IL2v(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA FAP-IL2v
GTTS-WQ11368MR IVTScrip™ mRNA-Anti-IGF, MEDI-573(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MEDI-573
GTTS-WQ14381MR IVTScrip™ mRNA-Anti-TNF, r-hTBP-1(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA r-hTBP-1
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW